Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10634927 | 0.84 | HRH4 (0.47) | HRH4HRH3LMNAHSD11B1 | |
| SCHEMBL13714953 | 0.83 | HRH4 (0.56) | HRH4HRH3KMT2A | |
| SCHEMBL10112201 | 0.77 | HSD11B1 (0.60) | CCR5ALDH1A1DUSP3PTPN5PTPN11 | |
| SCHEMBL21710448 | 0.71 | CCR5 (0.52) | CCR5 | |
| SCHEMBL4195672 | 0.71 | MGLL (0.57) | POLBKMT2AMGLLHSD11B1SLC18A3 | |
| SCHEMBL10200570 | 0.70 | DUSP3 (0.69) | ALDH1A1DUSP3PTPN5PTPN11HRH4 | |
| SCHEMBL10200555 | 0.70 | DUSP3 (0.69) | ALDH1A1DUSP3PTPN5PTPN11HRH4 | |
| SCHEMBL16285313 | 0.70 | HRH4 (0.52) | ALDH1A1HRH4HRH3POLBKMT2A | |
| SCHEMBL11200819 | 0.70 | HRH4 (0.49) | ALDH1A1HRH4HRH3KMT2ALMNA | |
| SCHEMBL13636392 | 0.70 | LMNA (0.42) | CCR5ALDH1A1HRH4POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | CCR5 558/4885ALDH1A1 1148/4885DUSP3 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.